Vaccination programs against COVID-19 have been implemented all over the world since December 2020. Beside the common side effects of vaccines, there are also increasing reports of herpes zoster (HZ) activation. In this report, we describe three cases of HZ, one of them with post-herpetic neuralgia (PHN) after receiving inactivated COVID-19 vaccine. The first two patients developed HZ 8 and 10 days after vaccination, respectively. When pain could not be controlled with paracetamol and non-steroidal anti-inflammatories, the patients received weak opioid codeine. In addition, the first patient received gabapentin, and the second patient was applied erector spinae plane block. The third patient was admitted 4 months after the diagnosis of HZ and considered to have PHN and pain palliation was provided with tramadol. Although the exact cause has not yet been fully resolved, increased reports of HZ after vaccination suggests a link between vaccines and HZ. Considering that receiving COVID-19 vaccines will going on, HZ and PHN cases will continue to be seen. More epidemiological studies are needed to further evaluate the relationship between COVID-19 vaccines and HZ.

Download full-text PDF

Source
http://dx.doi.org/10.14744/agri.2021.66642DOI Listing

Publication Analysis

Top Keywords

inactivated covid-19
8
herpes zoster
8
post-herpetic neuralgia
8
reports vaccination
8
covid-19 vaccines
8
covid-19 vaccine-related
4
vaccine-related herpes
4
zoster post-herpetic
4
neuralgia three
4
three case
4

Similar Publications

Capsid Integrity qPCR (CI-qPCR) assays offer a promising alternative to cell culture-based infectivity assays for assessing pathogenic human virus viability in wastewater. This study compared three CI-qPCR methods: two novel (Crosslinker, TruTiter) and one established (PMAxx dye). These methods were evaluated on heat-inactivated and non-heat-inactivated 'live' viruses spiked into phosphate-buffered saline (PBS) and wastewater, as well as on viruses naturally present in wastewater samples.

View Article and Find Full Text PDF

Development of a two-component recombinant vaccine for COVID-19.

Front Immunol

January 2025

Innovation Institute for Artificial Intelligence in Medicine and Zhejiang Provincial Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.

Introduction: Though COVID-19 as a public health emergency of international concern (PHEIC) was declared to be ended by the WHO, it continues to pose a significant threat to human society. Vaccination remains one of the most effective methods for preventing COVID-19. While most of the antigenic regions are found in the receptor binding domain (RBD), the N-terminal domain (NTD) of the S protein is another crucial region for inducing neutralizing antibodies (nAbs) against COVID-19.

View Article and Find Full Text PDF

The only way to mitigate the spread of coronavirus disease 2019 (COVID-19) pandemic was vaccines. While effective in decreasing the rate and severity of the disease, there also have been considerable adverse events. Since the birth of vaccines, adverse reactions accompanied the immunity, and COVID-19 vaccines are no exceptions.

View Article and Find Full Text PDF

Neutralizing antibody test supports booster strategy for young individuals after SARS-CoV-2 Omicron breakthrough.

Eur J Med Res

January 2025

Department of Ophthalmology, The First Affiliated Hospital of USTC, School of Life Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230026, China.

Background: The SARS-CoV-2 Omicron variant, since its initial detection, has rapidly spread across the globe, becoming the dominant strain. It is important to study the immune response of SARS-CoV-2 Omicron variant due to its remarkable ability to escape the majority of existing SARS-CoV-2 neutralizing antibodies. The surge in SARS-CoV-2 Omicron infections among most Chinese residents by the end of 2022 provides a unique opportunity to understand immune system's response to Omicron in populations with limited exposure to prior SARS-CoV-2 variants.

View Article and Find Full Text PDF

Assessment of the impact of different SARS-CoV-2 inactivation operations on colistin sulfate plasma concentration results.

BMC Infect Dis

January 2025

Department of Cardiac Surgery, Second Hospital of Hebei Medical University, No.215 of Heping West Road,Xinhua District, Shijiazhuang, 050000, China.

Objective: To evaluate the effects of different SARS-CoV-2 inactivation methods on the blood concentration of colistin sulfate.

Methods: A colistin sulfate reference substance, a quality control plasma sample, and a clinically measured sample were transferred and heated in a 56 °C water batch for 30 min or irradiated under an ultraviolet (UV) lamp for 60 min to examine the stability of the reference solution and quality control plasma sample. Statistical analysis was conducted for the concentration of the clinically measured sample before and after inactivation with the intraclass correlation coefficient (ICC) method, the Passing-Bablok regression, and the Bland-Altman analysis.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!